POST COVID MANAGEMENT OF ASTHMA IN CHRONIC ASTHMA PATIENT

PDF

Published: 2021-12-24

Page: 454-461


RAJAT DASH

GCP, SBP, Odisha, India.

B. RAY *

Post Graduate Department, GCP, SBP, Odisha, India.

S. N. DAS

Post Graduate Department, GCP, SBP, Odisha, India.

SWASTIK KUMAR PUROHIT

GCP, SBP, Odisha, India.

*Author to whom correspondence should be addressed.


Abstract

Asthma is defined as a chronic inflammatory disease of the airways. The chronic inflammation is associated with airway hyper responsiveness (an exaggerated airway narrowing response to triggers, such as allergens and exercise), that leads to recurrent symptoms such as wheezing, dyspnea (shortness of breath), chest tightness and coughing. Asthma is associated with T helper cell type-2 (Th2) immune responses, which are typical of other atopic conditions. Various allergic (e.g., dust mites, cockroach residue, furred animals, moulds, pollens) and non-allergic (e.g., infections, tobacco smoke, cold air, exercise) triggers produce a cascade of immune-mediated events leading to chronic airway inflammation. The Present Review Discuss and Focus about the various Risk factor associated with Covid 19 influenced Asthma Patient with their Possible Management.

Keywords: Asthma, allergy, antigene, antibody, immunnity, cytokines


How to Cite

DASH, R., RAY, B., DAS, S. N., & PUROHIT, S. K. (2021). POST COVID MANAGEMENT OF ASTHMA IN CHRONIC ASTHMA PATIENT. Asian Journal of Advances in Medical Science, 3(1), 454–461. Retrieved from https://mbimph.com/index.php/AJOAIMS/article/view/2696

Downloads

Download data is not yet available.

References

World Health Organization. WHO Director-General’s opening remarks at the media briefing on COVID-19 - 11 March 2020. Available:https://www.who.int/dg/ speeches/detail/who-director-general-s-opening-remarksat-the-media-briefing-on-covid-19---11-march-2020 Accessed 15th Mar 2020.

Centers for Disease Control and Prevention. Coronavirus disease 2019 (COVID-19) situation summary Available: https://www.cdc.gov/coronavirus/2019-ncov/ index.html Accessed 15th Mar 2020

Coates AL, Wanger J, Cockcroft DW, Culver BH; and the Bronchoprovocation Testing Task Force: Kai-Håkon Carlsen, Diamant Z, Gauvreau G, Hall GL, Hallstrand TS, HorvathI, de Jongh FHC, Joos G, Kaminsky DA, Laube BL, Leuppi JD, Sterk PJ: ERS technical standard on bronchial challenge testing: general considerations and performance of methacholine challenge tests. Eur Respir J. 2017;49:pii 1601526.

Newman KB, Milne S, Hamilton C, Hall K. A comparison of albuterol administered by metered-dose inhaler and spacer with albuterol by nebulizer in adults presenting to an urban emergency department with acute asthma. Chest. 2002;121:1036–1041.

Travers AH, Milan SJ, Jones AP, Camargo CA Jr, Rowe BH. Addition of intravenous beta(2)-agonists to inhaled beta(2)-agonists for acute asthma. Cochrane Database Syst Rev 2012;12:CD010179.

Manser R, Reid D, Abramson M: Corticosteroids for acute severe asthma in hospitalised patients. Cochrane Database Syst Rev. 2001; 1:CD001740.

Zhang JJ, Dong X, Cao YY, Yuan YD, Yang YB, Yan YQ, et al. Clinical characteristics of 140 patients infected with SARSCoV-2 in Wuhan, China. Allergy 2020. DOI: 10.1111/ all.14238

Huang K, Yang T, Xu J, et al. Prevalence, risk factors, and management of asthma in China: a national cross-sectional study. Lancet. 2019;394:407-18.

Garg S, Kim L, Whitaker M, O’Halloran A, Cummings C, Holstein R, et al. Hospitalization rates and characteristics of patients hospitalized with laboratory-confirmed coronavirus disease 2019 - COVID-NET, 14 States, March 1-30, 2020. MMWR Morb Mortal Wkly Rep. 2020;69(15):458-64. DOI: 10.15585/ mmwr.mm6915e3.

Emami A, Javanmardi F, Pirbonyeh N, Akbari A. Prevalence of underlying diseases in hospitalized patients with COVID-19: a systematic review and meta-analysis. Arch Acad Emerg Med. 2020;8(1):e35. ECollection; 2020.

Williamson E, Walker AJ, Bhaskaran K, Bacon S, Bates C, Morton CE, et al. OpenSAFELY: factors associated with COVID-19-related hospital death in the linked electronic health records of 17 million adult NHS patients. COVID19 SARS-CoV-2 preprints from medRxiv and bioRxiv 2020. DOI: 10.1101/2020.05.06.20092999

Konopka KE, Wilson A, Myers JL. Postmortem lung findings in an asthmatic with coronavirus disease 2019 (COVID19). Chest 2020 pii: S0012-3692(20)30775-3. DOI: 10.1016/j.chest.2020.04.032

Rowe BH, Spooner CH, Ducharme FM, Bretzlaff JA, Bota GW. Corticosteroids for preventing relapse following acute exacerbations of asthma. Cochrane Database Syst Rev. 2007;3:CD000195.

Hasegawa T, Ishihara K, Takakura S, Fujii H, Nishimura T, Okazaki M, Katakami N, Umeda B: Duration of systemic corticosteroids in the treatment of asthma exacerbation; a randomized study. Intern Med. 2000;39: 794–797.

Jones AM, Munavvar M, Vail A, Aldridge RE, Hopkinson L, Rayner C, O’Driscoll BR: Prospective, placebo-controlled trial of 5 vs 10 days of oral prednisolone in acute adult asthma. Respir Med. 2002;96:950–954.

Edmonds ML, Milan SJ, Camargo CA Jr, Pollack CV, Rowe BH: Early use of inhaled corticosteroids in the emergency department treatment of acute asthma. Cochrane Database Syst Rev. 2012;12:CD002308.

Halpin DMG, Faner R, Sibila O, Badia JR, Agusti A. Do chronic respiratory diseases or their treatment affect the risk of SARS-CoV-2 infection? Lancet Respir Med. 2020;8(5):436-8.

Yamaya M, Nishimura H, Deng X, Sugawara M, Watanabe O, Nomura K, et al. Inhibitory effects of glycopyrronium, formoterol, and budesonide on coronavirus HCoV-229E replication and cytokine production by primary cultures of human nasal and tracheal epithelial cells. Respir Investig 2020. Epub 2020/02/26.

Matsuyama S, Kawase M, Nao N, Shirato K, Ujike M, Kamitani W, et al. The inhaled corticosteroid ciclesonide blocks coronavirus RNA replication by targeting viral NSP15. bioRxiv 2020. DOI: 10.1101/2020.03.11.987016.

Simpson JL, Carroll M, Yang IA, Reynolds PN, Hodge S, James AL, et al. Reduced antiviral interferon production in poorly controlled asthma is associated with neutrophilic inflammation and high-dose inhaled corticosteroids. Chest. 2016;149(3):704-13.

Matsuyama S, Kawase M, Nao N, Shirato K, Ujike M, Kamitani W, et al. The inhaled corticosteroid ciclesonide blocks coronavirus RNA replication by targeting viral NSP15. bioRxiv 2020. DOI: 10.1101/2020.03.11.987016.

Gibson PG, Yang IA, Upham JW, Reynolds PN, Hodge S, James AL, et al. Effect of azithromycin on asthma exacerbations and quality of life in adults with persistent uncontrolled asthma (AMAZES): a randomised, doubleblind, placebo-controlled trial. Lancet. 2017;390(10095):659- 68.

Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention. Available: www. ginaasthma.org

Williamson E, Walker AJ, Bhaskaran K, et al. OpenSAFELY: factors associated with COVID-19-related hospital death in the linked electronic health records of 17 million adult NHS patients. medRxiv. 2020. DOI:https://doi.org/10.1101/2020.05.06.20092999

Pelletier JH, Rakkar J, Au AK, Fuhrman D, Clark RSB, Horvat CM. Trends in US pediatric hospital admissions in 2020 compared with the decade before the COVID–19 pandemic. JAMA Netw Open. 2021;4:e2037227.

Lemanske RF, Busse WW: Asthma: Clinical expression and molecular mechanisms. J Allergy Clin Immunol. 2010;125:S95-102.

Lougheed MD, Lemière C, Dell SD, Ducharme FM, Fitzgerald JM, Leigh R, Licskai C, Rowe BH, Bowie D, Becker A, Boulet LP: Canadian Thoracic Society asthma management continuum: 2010 consensus summary for children six years of age and over, and adults. Can Respir J. 2010;17:15-24.

Kaplan AG, Balter MS, Bell AD, Kim H, McIvor RA: Diagnosis of asthma in adults. CMAJ. 2009; 181:E210-E220.

Haahtela T, Tuomisto LE, Pietinalho A, Klaukka T, Erhola M, Kaila M, Nieminen MM, Kontula E, Laitinen LA. A 10 year asthma programme in Finland: major change for the better. Thorax. 2006;61:663–670.

Price D, Robertson A, Bullen K, Rand C, Horne R, Staudinger H. Improved adherence with once-daily versus twice- daily dosing of mometasone furoate administered via a dry powder inhaler: a randomized openlabel study. BMC Pulm Med. 2010;10:1.

Powell H, Gibson PG. Options for self-management education for adults with asthma. Cochrane Database Syst Rev. 2003;1:CD004107.

Gibson PG, Powell H, Coughlan J, Wilson AJ, Abramson M, Haywood P, Bauman A, Hensley MJ, Walters EH. Self-management education and regular practitioner review for adults with asthma. Cochrane Database Syst Rev. 2003;1:CD001117.

McLean S, Chandler D, Nurmatov U, Liu J, Pagliari C, Car J, Sheikh A. Telehealthcare for asthma. Cochrane Database Syst Rev. 2010;10:CD007717.

Boulet LP: Influence of comorbid conditions on asthma. Eur Respir J. 2009;33:897–906.

Kiljander TO, Harding SM, Field SK, Stein MR, Nelson HS, Ekelund J, Illueca M, Beckman O, Sostek MB: Effects of esomeprazole 40 mg twice daily on asthma: a randomized placebo-controlled trial. Am J Respir Crit Care Med. 2006;173:1091– 1097.

Hatoun J, Correa ET, Donahue SMA, Vernacchio L. Social disHatoun J, Correa ET, Donahue SMA, Vernacchio L. Social distancing for COVID–19 and diagnoses of other infectious diseases in children. Pediatrics. 2020;146:e2020006460.

Rodrigo GJ, Castro-Rodriguez JA. Anticholinergics in the treatment of children and adults with acute asthma: a systematic review with meta-analysis. Thorax. 2005;60: 740–746.

Rowe BH, Bretzlaff JA, Bourdon C, Bota GW, Camargo CA Jr. Magnesium sulfate for treating exacerbations of acute asthma in the emergency department. Cochrane Database Syst Rev. 2000;2:CD001490.

Gallegos-Solórzano MC, Pérez-Padilla R, Hernández-Zenteno RJ. Usefulness of inhaled magnesium sulfate in the coadjuvant management of severe asthma crisis in an emergency department. Pulm Pharmacol Ther. 2010;23:432–437.

Schatz M, Rachelefsky G, Krishnan JA: Follow-up after acute asthma episodes: what improves future outcomes? Proc Am Thorac Soc. 2009;6:386–393.

Ding Y, Yan H, Guo W. Clinical characteristics of children with COVID–19: a meta-analysis. Front Pediatr. 2020;8:431.

Nallasamy K, Angurana SK, Jayashree M, et al. Pediatric COVID Management Team. Clinical profle, hospital course and outcome of children with COVID–19. Indian J Pediatr. 2021;88:979–84

Zimmermann P, Curtis N. Coronavirus infections in children including COVID-19: an overview of the epidemiology, clinical features, diagnosis, treatment and prevention options in children. Pediatr Infect Dis J. 2020;39:355–68

Singh P, Attri K, Mahto D, et al. Clinical profle of COVID–19 illness in children-experience from a tertiary care hospital. Indian J Pediatr; 2021. DOI:https://doi.org/10.1007/s12098-021-03822-5

Lodha R, Kabra SK. COVID–19 pandemic: impact on health care of children and the urgent need to restore regular healthcare services. Indian J Pediatr. 2021;88:225

Li X, Xu S, Yu M, et al. Risk factors for severity and mortality in adult COVID–19 inpatients in Wuhan. J Allergy Clin Immunol. 2020;146:110–8.

Sunjaya AP, Allida SM, Di Tanna GL, Jenkins C. Asthma and risk of infection, hospitalization, ICU admission and mortality from COVID–19: systematic review and meta–analysis. J Asthma. 2021;1–14. DOI:https://doi.org/10.1080/02770903.2021.1888116.

Castro-Rodriguez JA, Forno E. Asthma and COVID–19 in children: a systematic review and call for data. Pediatr Pulmonol. 2020;55:2412–8.

Simoneau T, Greco KF, Hammond A, Nelson K, Gafn JM. Impact of the COVID–19 pandemic on pediatric emergency department utilization for asthma. Ann Am Thorac Soc. 2020;18:717–9.

Alsulaiman JW, Kheirallah KA, Ajlony MJ, Al-Tamimi TM, Khasawneh RA, Al-Natour L. Paediatric asthma exacerbation admissions and stringency of non-pharmaceutical interventions: results from a developing country. Int J Clin Pract. 2021;75:e14423.

Foley DA, Yeoh DK, Minney-Smith CA, et al. The interseasonal resurgence of respiratory syncytial virus in australian children following the reduction of coronavirus disease 2019-related public health measures. Clin Infect Dis.; 2021. DOI:https://doi.org/10.1093/cid/ciaa1906.

Strausz S, Kiiskinen T, Broberg M, et al. Sleep apnoea is a risk factor for severe COVID–19. BMJ Open Respir Res. 2021;8:e000845.

Jenssen BP, Kelly MK, Powell M, Bouchelle Z, Mayne SL, Fiks AG. COVID–19 and changes in child obesity. Pediatrics. 2021;147:e2021050123.

Weinstein SM, Pugach O, Rosales G, Mosnaim GS, Walton SM, Martin MA. Family chaos and asthma control. Pediatrics. 2019;144:e20182758.

Marques de Miranda D, da Silva Athanasio B, Sena Oliveira AC, Simoes-E-Silva AC. How is COVID-19 pandemic impacting mental health of children and adolescents? Int J Disaster Risk Reduct. 2020;51:101845.